Loading...
XTSX
EBM
Market cap48mUSD
Jul 09, Last price  
1.00CAD
1D
0.00%
1Q
17.65%
IPO
-60.00%
Name

Eastwood Bio-Medical Canada Inc

Chart & Performance

D1W1MN
XTSX:EBM chart
P/E
P/S
88.08
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
1.71%
Revenues
782k
+11.40%
580,321461,5111,186,098463,933479,729743,9731,292,894718,336981,0511,299,763867,936702,076782,080
Net income
-333k
L-27.00%
-139,282-519,098-260,381-468,479-489,624-861,977-579,677-860,030-611,336-160,584-546,598-455,870-332,767
CFO
19k
P
-252,8841,577,699-270,508-306,577-355,279-454,790-178,129-542,694-116,214-4,294-16,888-15,21719,303

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Eastwood Bio-Medical Canada Inc., established in Richmond, Canada, in 2010, is a company focused on the worldwide marketing and distribution of natural health products. Operating under the Eleotin brand, their offerings are available across Canada, the United States, and Asian regions. The firm's core mission is to deliver natural remedies for prevalent metabolic disorders, including issues with blood glucose regulation, hypertension, and obesity. Their extensive portfolio of licensed Eleotin products addresses diverse health requirements. For individuals experiencing spleen deficiency, appetite loss, or fatigue, Eleotin A 700 provides support. Eleotin AL88 serves as a laxative, while Eleotin Cal20 aids in the maintenance of healthy bones and teeth. Eleotin V3D is formulated for the development and upkeep of strong bones, teeth, and overall well-being. To support cardiovascular health, they offer Eleotin G2000. Eleotin H55 is designed to act as a sedative and alleviate tension, and Eleotin Zn330 is vital for tissue formation and metabolic processes. Furthermore, their product line includes Eleotin Bentley, which promotes balanced glucose levels, and Eleotin LBM, intended for hypertension relief.
IPO date
Sep 05, 2014
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑102024‑102023‑102022‑102021‑102020‑102019‑102018‑102017‑102016‑10
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT